MAO type B inhibitors as adjunct to L-dopa therapy.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000480:Alkynes / Q000627:therapeutic use; D000818:Animals; D001921:Brain / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D007527:Isoenzymes / Q000378:metabolism; D007980:Levodopa / Q000627:therapeutic use*; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010293:Pargyline / Q000031:analogs & derivatives*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D010302:Parkinson Disease, Secondary / Q000188:drug therapy / Q000201:enzymology; D011725:Pyridines / Q000633:toxicity; D011954:Receptors, Dopamine / Q000187:drug effects; D012642:Selegiline / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D014439:Tyramine / Q000037:antagonists & inhibitors
D000480:Alkynes; D007189:Indans; D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors; D011725:Pyridines; D011954:Receptors, Dopamine; C031967:rasagiline; D012642:Selegiline; D007980:Levodopa; C025253:N-methyl-N-propargyl-(1-indanyl)-ammonium hydrochloride; D010293:Pargyline; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; D014439:Tyramine